Anxiety and Related Sleep Disorders - Mexico

Revenue in the Anxiety and Related Sleep Disorders market is projected to reach US$125.80m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.14%, resulting in a market volume of US$126.70m by 2029.
In global comparison, most revenue will be generated United States (US$3.21bn in 2024).
In relation to total population figures, per person revenues of US$19.72 are generated in 2024.

The Anxiety and Related Sleep Disorders market covers sales of three drug classes: anxiolytics, hypnotics, and sedatives. These classes contain different types of drugs, such as benzodiazepines, anticonvulsants, and antihistamines, that reduce anxiety and insomnia symptoms caused by anxiety. These medications mainly fall into the category of prescription drugs.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, GlaxoSmithKline PLC, Johnson & Johnson, and Merck & Co.

Pharmaceutical sales and consumption of anxiolytics
Pharmaceutical sales and consumption hypnotics and sedatives

Non-mental health related sleep disorders
Any other anxiety medications
Psychotherapy

The Anxiety and Related Sleep Disorders market in Mexico is experiencing significant growth and development.

Customer preferences: Mexican consumers are increasingly becoming aware of the importance of mental health and the impact it has on overall well-being. As a result, there is a growing demand for products and services that address anxiety and related sleep disorders. Consumers are seeking effective and convenient solutions to manage their anxiety and improve their sleep quality. They are looking for products that are natural, safe, and have minimal side effects. Additionally, there is a preference for products that are easy to use and can be accessed without a prescription.

Trends in the market: One of the key trends in the Anxiety and Related Sleep Disorders market in Mexico is the growing popularity of natural remedies. Consumers are gravitating towards herbal supplements, aromatherapy, and other alternative therapies to manage their anxiety and sleep disorders. This trend is driven by a desire for holistic and sustainable approaches to health and wellness. Additionally, there is a growing interest in technology-based solutions such as mobile applications and wearable devices that help track and manage anxiety and sleep patterns.

Local special circumstances: Mexico has a high prevalence of anxiety and related sleep disorders, which contributes to the growth of the market. Factors such as work-related stress, social pressures, and lifestyle changes have led to an increase in the number of individuals seeking treatment for anxiety and sleep disorders. The Mexican healthcare system has also recognized the importance of mental health and has implemented initiatives to improve access to treatment and support services.

Underlying macroeconomic factors: The growing Anxiety and Related Sleep Disorders market in Mexico can be attributed to several macroeconomic factors. Firstly, the increasing disposable income and changing lifestyles of Mexican consumers have allowed them to prioritize their mental health and well-being. Secondly, the rise of e-commerce and online platforms has made it easier for consumers to access a wide range of products and services related to anxiety and sleep disorders. Lastly, the government's focus on improving healthcare infrastructure and increasing awareness about mental health has also contributed to the growth of the market.Overall, the Anxiety and Related Sleep Disorders market in Mexico is witnessing significant growth due to changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors. As the market continues to evolve, there is a need for companies to innovate and develop products and services that cater to the specific needs and preferences of Mexican consumers.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.